Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients

被引:83
作者
Colombo, P. -E. [1 ]
Mourregot, A. [1 ]
Fabbro, M. [2 ]
Gutowski, M. [1 ]
Saint-Aubert, B. [1 ]
Quenet, F. [1 ]
Gourgou, S. [3 ]
Rouanet, P. [1 ]
机构
[1] CRLC Val Aurelle, Dept Surg Oncol, F-34298 Montpellier 5, France
[2] CRLC Val Aurelle, Dept Med Oncol, F-34298 Montpellier 5, France
[3] CRLC Val Aurelle, Dept Biostat, F-34298 Montpellier 5, France
来源
EJSO | 2009年 / 35卷 / 02期
关键词
Advanced ovarian cancer; Cytoreductive surgery; Initial surgery; Interval surgery; LONG-TERM SURVIVAL; PRIMARY CYTOREDUCTIVE SURGERY; INTERVAL DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; GYNECOLOGIC ONCOLOGY; RESIDUAL DISEASE; CARCINOMA; MANAGEMENT; IMPACT;
D O I
10.1016/j.ejso.2008.01.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: The standard treatment for advanced ovarian cancer consists of cytoreductive surgery associated with a platinum/paclitaxel-based chemotherapy. Nevertheless, there is still the question as to the extent and timing of the surgical debulking. The aim of this study was to evaluate the place of surgery in the therapeutic sequence. Patients and methods: We reviewed data from all consecutive patients with stage IIIC and IV epithelial ovarian cancer, operated on at our institution between 1990 and 2005. Patients were divided into 2 groups, according to the position of surgery in the therapeutic sequence. Patients in group 1 received initial debulking surgery. Group 2 consisted of patients having received their first debulking after initial chemotherapy. Results: Two hundred and three patients were identified and frequently underwent aggressive surgery, in particular, digestive surgery with bowel resections. Petioperative mortality and morbidity rates were low (2% and 14%, respectively) and there was no difference between the groups. Overall survival in group I for patients with complete cytoreduction (residual disease (RD) = 0). optimal surgery (RD < 1 cm) or sub-optimal surgery (RD > 1 cm) Was 50%, 30% and 14%, respectively. In group 2, overall survival following complete surgery was 30%, and no lone-term survival was observed when surgery was not complete at the time of interval surgery. Survival was worse for patients who had received more than 4 cycles of neoadjuvant chemotherapy. Conclusion: This study confirms the importance of surgery in the prognosis of advanced ovarian cancer. Only the patient subgroup that underwent complete initial or interval surgery was associated with a prolonged remission. Optimal surgery with a controlled morbidity can he achieved in many cases, even if bowel resection is needed. at the time of primary debulking. In the interval cytoreductive surgery subgroup, the response to initial chemotherapy and surgery was found to be essential for prognosis. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:135 / 143
页数:9
相关论文
共 57 条
[1]   Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon [J].
Aletti, GD ;
Gostout, BS ;
Podratz, KC ;
Cliby, WA .
GYNECOLOGIC ONCOLOGY, 2006, 100 (01) :33-37
[2]   Diagnostic open laparoscopy in the management of advanced ovarian cancer [J].
Angioli, R ;
Palaia, I ;
Zullo, MA ;
Muzii, L ;
Manci, N ;
Calcagno, M ;
Panici, PB .
GYNECOLOGIC ONCOLOGY, 2006, 100 (03) :455-461
[3]  
Ansquer Y, 2001, CANCER, V91, P2329, DOI 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO
[4]  
2-U
[5]   TUMOR REDUCTION SURGERY AND LONG-TERM SURVIVAL IN ADVANCED OVARIAN-CANCER - A DACOVA STUDY [J].
BERTELSEN, K .
GYNECOLOGIC ONCOLOGY, 1990, 38 (02) :203-209
[6]   Diagnosis and management of epithelial ovarian cancer [J].
Bhoola, Snehal ;
Hoskins, William J. .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (06) :1399-1410
[7]  
Bristow RE, 2000, CANCER, V89, P1532, DOI 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO
[8]  
2-A
[9]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[10]   Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis [J].
Bristow, Robert E. ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1070-1076